Sleep stage-dependent distribution of interictal epileptiform discharges in epilepsy: A systematic review.

Epilepsy BehavJul 31, 2026 (epub)
Clinical ResearchNeurology

Ximena Blasco, Emmanuel Polito-Salazar, Marian Lázaro et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the distribution of interictal epileptiform discharges (IED) across sleep stages in 266 patients with epilepsy. The analysis revealed that IED rates were significantly higher during NREM sleep compared to REM sleep (p = 0.0019). However, no significant difference was found between N2 and N3 sleep stages, despite slightly higher median spike rates in N3.

Key findings

  • IED rates were significantly higher during NREM than REM sleep (p = 0.0019).
  • Median spike rates were 0.99 IED/min during N3 and 0.86 IED/min during N2.
  • REM sleep exhibited the lowest IED activity.
  • The review included ten observational studies with a total of 266 patients.

Why it matters

Understanding the relationship between sleep stages and IED distribution can enhance the interpretation of EEG findings in epilepsy. This knowledge may inform clinical practices regarding the timing of EEG recordings to optimize diagnostic yield.

Source

PubMed · PMID 42537545

Published in Epilepsy Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.